What is the top biotech news this week?

Biotech is surging into the spotlight this week, with a landmark FDA approval, a major clinical trial readout, and a seismic M&A move reshaping the competitive landscape. The sector is firing on multiple cylinders, and investors and researchers alike have plenty to digest.

The biggest story centers on Eli Lilly, which received FDA approval for donanemab (branded as Kisunla) for early symptomatic Alzheimer's disease — a milestone that positions Lilly as a dominant force in the amyloid-targeting space alongside Biogen and Eisai's Leqembi. Reporting from STAT News highlighted that Kisunla's dosing flexibility and trial data showing patients can stop treatment once amyloid is cleared could differentiate it meaningfully in the clinic. This approval reignites debate about how neurologists will choose between competing therapies and whether payers like Medicare will broaden coverage criteria.

On the oncology front, Moderna released encouraging updated data from its personalized mRNA cancer vaccine program, developed in partnership with Merck. The combination of mRNA-4157 with Keytruda continued to show durable benefit in melanoma patients, and the companies announced expansion into lung and bladder cancers. Nature Medicine published supporting mechanistic data this week explaining how individualized neoantigen targeting amplifies T-cell responses — lending scientific credibility to what was once considered a moonshot approach. The mRNA-oncology pipeline is rapidly becoming one of the most watched spaces in all of biomedicine.

Meanwhile, AstraZeneca made headlines with its agreement to acquire Fusion Pharmaceuticals for approximately $2.4 billion, doubling down on targeted radioligand therapies (RLTs). This follows Novartis's dominance in the RLT space with Lutathera and Pluvicto, and signals that big pharma views radioligands as the next blockbuster modality. BioPharma Dive noted that the deal gives AstraZeneca access to Fusion's actinium-based platform, which may offer advantages over lutetium in penetrating solid tumors.

Watch closely for the upcoming PDUFA date for Vertex Pharmaceuticals' non-opioid pain drug suzetrigine — a potential category-defining approval that could disrupt analgesic prescribing patterns. If cleared, it would mark the first truly novel pain mechanism approved in decades, and the ripple effects across neuroscience pipelines would be immediate and significant.

— Pulse